Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL
Results From a Retrospective Real-World Study
Results From a Retrospective Real-World Study
According to a recent retrospective, real-world study, venetoclax-obinutuzumab treatment achieved frequent, durable, and safe responses among patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
This study included data from 40 patients with CLL/SLL being treated with venetoclax-obinutuzumab between July 2019 and June 2022. The median participant age was 72; 28.2% of patients had TP53 gene mutation and/or 17p deletion. It was recorded that the median number of prior therapies was 1, with a range of 1 to 6, and 55% had prior Bruton tyrosine kinase (BTK) inhibitor exposure.
Results demonstrated the overall response rate (ORR) was measured among 90% (complete response [CR] or CR with incomplete marrow recovery in 27.5% and partial response [PR] in 62.5%) of patients. The 2-year progression-free survival (PFS) was 81.2% (95% confidence interval [CI], 69.5 to 94.8).
Study results also noted that the therapy was well-tolerated by patients, and no laboratory or clinical tumor lysis syndrome (TLS) occurred with venetoclax, according to Howard criteria. However, 1 patient experienced laboratory TLS with obinutuzumab initiation.
Matthew M. Lei, PharmD, Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and colleagues concluded that, “This retrospective cohort study demonstrated that [venetoclax-obinutuzumab] achieves frequent, durable responses and can be safely administered in [R/R] CLL/SLL.”
Source:
Lei M, Sorial M, Lou U, et al. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leukemia & Lymphoma, doi: 10.1080/10428194.2024.2310144
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of OLN or HMP Global, their employees, and affiliates.
